Copyright Reports & Markets. All rights reserved.

Global T Cell Antigen Gp39 Market Professional Survey Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Industry Overview of T Cell Antigen Gp39

      • 1.1 Definition of T Cell Antigen Gp39
      • 1.2 T Cell Antigen Gp39 Segment by Type
        • 1.2.1 Global T Cell Antigen Gp39 Production Growth Rate Comparison by Types (2014-2025)
        • 1.2.2 ECI-006
        • 1.2.3 Hepatitis B vaccine
        • 1.2.4 INX-021
        • 1.2.5 ISF-35
        • 1.2.6 Others
      • 1.3 T Cell Antigen Gp39 Segment by Applications
        • 1.3.1 Global T Cell Antigen Gp39 Consumption Comparison by Applications (2014-2025)
        • 1.3.2 Graft Versus Host Disease
        • 1.3.3 Breast Cancer
        • 1.3.4 Bladder Cancer
        • 1.3.5 Panceratic Cancer
        • 1.3.6 Others
      • 1.4 Global T Cell Antigen Gp39 Overall Market
        • 1.4.1 Global T Cell Antigen Gp39 Revenue (2014-2025)
        • 1.4.2 Global T Cell Antigen Gp39 Production (2014-2025)
        • 1.4.3 North America T Cell Antigen Gp39 Status and Prospect (2014-2025)
        • 1.4.4 Europe T Cell Antigen Gp39 Status and Prospect (2014-2025)
        • 1.4.5 China T Cell Antigen Gp39 Status and Prospect (2014-2025)
        • 1.4.6 Japan T Cell Antigen Gp39 Status and Prospect (2014-2025)
        • 1.4.7 Southeast Asia T Cell Antigen Gp39 Status and Prospect (2014-2025)
        • 1.4.8 India T Cell Antigen Gp39 Status and Prospect (2014-2025)

      2 Manufacturing Cost Structure Analysis

      • 2.1 Raw Material and Suppliers
      • 2.2 Manufacturing Cost Structure Analysis of T Cell Antigen Gp39
      • 2.3 Manufacturing Process Analysis of T Cell Antigen Gp39
      • 2.4 Industry Chain Structure of T Cell Antigen Gp39

      3 Development and Manufacturing Plants Analysis of T Cell Antigen Gp39

      • 3.1 Capacity and Commercial Production Date
      • 3.2 Global T Cell Antigen Gp39 Manufacturing Plants Distribution
      • 3.3 Major Manufacturers Technology Source and Market Position of T Cell Antigen Gp39
      • 3.4 Recent Development and Expansion Plans

      4 Key Figures of Major Manufacturers

      • 4.1 T Cell Antigen Gp39 Production and Capacity Analysis
      • 4.2 T Cell Antigen Gp39 Revenue Analysis
      • 4.3 T Cell Antigen Gp39 Price Analysis
      • 4.4 Market Concentration Degree

      5 T Cell Antigen Gp39 Regional Market Analysis

      • 5.1 T Cell Antigen Gp39 Production by Regions
        • 5.1.1 Global T Cell Antigen Gp39 Production by Regions
        • 5.1.2 Global T Cell Antigen Gp39 Revenue by Regions
      • 5.2 T Cell Antigen Gp39 Consumption by Regions
      • 5.3 North America T Cell Antigen Gp39 Market Analysis
        • 5.3.1 North America T Cell Antigen Gp39 Production
        • 5.3.2 North America T Cell Antigen Gp39 Revenue
        • 5.3.3 Key Manufacturers in North America
        • 5.3.4 North America T Cell Antigen Gp39 Import and Export
      • 5.4 Europe T Cell Antigen Gp39 Market Analysis
        • 5.4.1 Europe T Cell Antigen Gp39 Production
        • 5.4.2 Europe T Cell Antigen Gp39 Revenue
        • 5.4.3 Key Manufacturers in Europe
        • 5.4.4 Europe T Cell Antigen Gp39 Import and Export
      • 5.5 China T Cell Antigen Gp39 Market Analysis
        • 5.5.1 China T Cell Antigen Gp39 Production
        • 5.5.2 China T Cell Antigen Gp39 Revenue
        • 5.5.3 Key Manufacturers in China
        • 5.5.4 China T Cell Antigen Gp39 Import and Export
      • 5.6 Japan T Cell Antigen Gp39 Market Analysis
        • 5.6.1 Japan T Cell Antigen Gp39 Production
        • 5.6.2 Japan T Cell Antigen Gp39 Revenue
        • 5.6.3 Key Manufacturers in Japan
        • 5.6.4 Japan T Cell Antigen Gp39 Import and Export
      • 5.7 Southeast Asia T Cell Antigen Gp39 Market Analysis
        • 5.7.1 Southeast Asia T Cell Antigen Gp39 Production
        • 5.7.2 Southeast Asia T Cell Antigen Gp39 Revenue
        • 5.7.3 Key Manufacturers in Southeast Asia
        • 5.7.4 Southeast Asia T Cell Antigen Gp39 Import and Export
      • 5.8 India T Cell Antigen Gp39 Market Analysis
        • 5.8.1 India T Cell Antigen Gp39 Production
        • 5.8.2 India T Cell Antigen Gp39 Revenue
        • 5.8.3 Key Manufacturers in India
        • 5.8.4 India T Cell Antigen Gp39 Import and Export

      6 T Cell Antigen Gp39 Segment Market Analysis (by Type)

      • 6.1 Global T Cell Antigen Gp39 Production by Type
      • 6.2 Global T Cell Antigen Gp39 Revenue by Type
      • 6.3 T Cell Antigen Gp39 Price by Type

      7 T Cell Antigen Gp39 Segment Market Analysis (by Application)

      • 7.1 Global T Cell Antigen Gp39 Consumption by Application
      • 7.2 Global T Cell Antigen Gp39 Consumption Market Share by Application (2014-2019)

      8 T Cell Antigen Gp39 Major Manufacturers Analysis

      • 8.1 Biogen, Inc.
        • 8.1.1 Biogen, Inc. T Cell Antigen Gp39 Production Sites and Area Served
        • 8.1.2 Biogen, Inc. Product Introduction, Application and Specification
        • 8.1.3 Biogen, Inc. T Cell Antigen Gp39 Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.1.4 Main Business and Markets Served
      • 8.2 Bristol-Myers Squibb Company
        • 8.2.1 Bristol-Myers Squibb Company T Cell Antigen Gp39 Production Sites and Area Served
        • 8.2.2 Bristol-Myers Squibb Company Product Introduction, Application and Specification
        • 8.2.3 Bristol-Myers Squibb Company T Cell Antigen Gp39 Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.2.4 Main Business and Markets Served
      • 8.3 eTheRNA Immunotherapies NV
        • 8.3.1 eTheRNA Immunotherapies NV T Cell Antigen Gp39 Production Sites and Area Served
        • 8.3.2 eTheRNA Immunotherapies NV Product Introduction, Application and Specification
        • 8.3.3 eTheRNA Immunotherapies NV T Cell Antigen Gp39 Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.3.4 Main Business and Markets Served
      • 8.4 ImmuNext, Inc.
        • 8.4.1 ImmuNext, Inc. T Cell Antigen Gp39 Production Sites and Area Served
        • 8.4.2 ImmuNext, Inc. Product Introduction, Application and Specification
        • 8.4.3 ImmuNext, Inc. T Cell Antigen Gp39 Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.4.4 Main Business and Markets Served
      • 8.5 Juno Therapeutics Inc.
        • 8.5.1 Juno Therapeutics Inc. T Cell Antigen Gp39 Production Sites and Area Served
        • 8.5.2 Juno Therapeutics Inc. Product Introduction, Application and Specification
        • 8.5.3 Juno Therapeutics Inc. T Cell Antigen Gp39 Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.5.4 Main Business and Markets Served
      • 8.6 MedImmune, LLC
        • 8.6.1 MedImmune, LLC T Cell Antigen Gp39 Production Sites and Area Served
        • 8.6.2 MedImmune, LLC Product Introduction, Application and Specification
        • 8.6.3 MedImmune, LLC T Cell Antigen Gp39 Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.6.4 Main Business and Markets Served
      • 8.7 Targovax AS
        • 8.7.1 Targovax AS T Cell Antigen Gp39 Production Sites and Area Served
        • 8.7.2 Targovax AS Product Introduction, Application and Specification
        • 8.7.3 Targovax AS T Cell Antigen Gp39 Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.7.4 Main Business and Markets Served
      • 8.8 XL-protein GmbH
        • 8.8.1 XL-protein GmbH T Cell Antigen Gp39 Production Sites and Area Served
        • 8.8.2 XL-protein GmbH Product Introduction, Application and Specification
        • 8.8.3 XL-protein GmbH T Cell Antigen Gp39 Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.8.4 Main Business and Markets Served

      9 Development Trend of Analysis of T Cell Antigen Gp39 Market

      • 9.1 Global T Cell Antigen Gp39 Market Trend Analysis
        • 9.1.1 Global T Cell Antigen Gp39 Market Size (Volume and Value) Forecast 2019-2025
      • 9.2 T Cell Antigen Gp39 Regional Market Trend
        • 9.2.1 North America T Cell Antigen Gp39 Forecast 2019-2025
        • 9.2.2 Europe T Cell Antigen Gp39 Forecast 2019-2025
        • 9.2.3 China T Cell Antigen Gp39 Forecast 2019-2025
        • 9.2.4 Japan T Cell Antigen Gp39 Forecast 2019-2025
        • 9.2.5 Southeast Asia T Cell Antigen Gp39 Forecast 2019-2025
        • 9.2.6 India T Cell Antigen Gp39 Forecast 2019-2025
      • 9.3 T Cell Antigen Gp39 Market Trend (Product Type)
      • 9.4 T Cell Antigen Gp39 Market Trend (Application)
      • 10.1 Marketing Channel
        • 10.1.1 Direct Marketing
        • 10.1.2 Indirect Marketing
      • 10.3 T Cell Antigen Gp39 Customers

      11 Market Dynamics

      • 11.1 Market Trends
      • 11.2 Opportunities
      • 11.3 Market Drivers
      • 11.4 Challenges
      • 11.5 Influence Factors

      12 Conclusion

        13 Appendix

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        The global T Cell Antigen Gp39 market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
        This report focuses on T Cell Antigen Gp39 volume and value at global level, regional level and company level. From a global perspective, this report represents overall T Cell Antigen Gp39 market size by analyzing historical data and future prospect.
        Regionally, this report categorizes the production, apparent consumption, export and import of T Cell Antigen Gp39 in North America, Europe, China, Japan, Southeast Asia and India.
        For each manufacturer covered, this report analyzes their T Cell Antigen Gp39 manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

        The following manufacturers are covered:
        Biogen, Inc.
        Bristol-Myers Squibb Company
        eTheRNA Immunotherapies NV
        ImmuNext, Inc.
        Juno Therapeutics Inc.
        MedImmune, LLC
        Targovax AS
        XL-protein GmbH

        Segment by Regions
        North America
        Europe
        China
        Japan
        Southeast Asia
        India

        Segment by Type
        ECI-006
        Hepatitis B vaccine
        INX-021
        ISF-35
        Others

        Segment by Application
        Graft Versus Host Disease
        Breast Cancer
        Bladder Cancer
        Panceratic Cancer
        Others

        Buy now